Publication Guide
Mary Ann Liebert, Inc. has been a fixture of specialty biomedical publishing since 1980, when its founder - one of the few women to build an academic publishing house from scratch - launched the company in New Rochelle, New York. Its first title, the Journal of Interferon Research, appeared in 1981, and the strategy has stayed consistent ever since: find emerging niches that larger publishers overlook and build the field's journal of record. That approach produced early journals in genetic engineering, gene therapy, tissue engineering, telemedicine, and more recently cannabis science and CRISPR research.
In December 2024 Sage acquired Mary Ann Liebert, Inc. The roughly 90 peer-reviewed journals continue to publish under the Mary Ann Liebert name as part of Sage, and the journal platform has moved to Sage's infrastructure (liebertpub.com now resolves to the Sage Journals site). This guide covers what that means for authors in 2026: choosing a journal, open-access options and APCs, peer review, and how to submit.
Which Mary Ann Liebert journal fits your paper?
Liebert's portfolio is narrow but deep - most titles are the leading or founding journal of a specific biomedical niche. Use the routes below to shortlist.
| You're most likely to... | Choose this route |
|---|---|
| Have clinical or translational neuroscience trauma research | Journal of Neurotrauma - the field's core title; Neurotrauma Reports is its fully-OA companion (~$1,750 APC). |
| Work on gene or cell therapy | Human Gene Therapy family - research, methods, and clinical development sections. |
| Work in redox biology or free-radical research | Antioxidants & Redox Signaling - among the highest-cited Liebert titles. |
| Study HIV/AIDS virology or epidemiology | AIDS Research and Human Retroviruses - one of Liebert's longest-running flagships. |
| Do regenerative medicine or biomaterials work | Tissue Engineering (Parts A, B, and C cover research, reviews, and methods). |
| Have thyroid, endocrine, or palliative-care clinical research | Thyroid (official ATA journal) or Journal of Palliative Medicine; both have OA 'Reports' companions. |
| Need a fully open-access venue with a modest APC | The 'Reports' family - Neurotrauma Reports, Palliative Medicine Reports, Women's Health Reports, Telemedicine Reports, Integrative Medicine Reports (~3,000). |
| Work on cannabis science or space/life sciences | Cannabis and Cannabinoid Research or Astrobiology - both field-defining Liebert titles. |
What Mary Ann Liebert actually publishes
~90 peer-reviewed journals, concentrated in biomedicine and biotechnology:
- Biomedical research and clinical medicine - AIDS Research and Human Retroviruses, Journal of Neurotrauma, Thyroid, Journal of Palliative Medicine, Journal of Women's Health, Surgical Infections.
- Biotechnology and life-science methods - Human Gene Therapy, Tissue Engineering, The CRISPR Journal (launched 2018), Assay and Drug Development Technologies, OMICS: A Journal of Integrative Biology.
- Emerging and interdisciplinary fields - Cannabis and Cannabinoid Research, Big Data, Telemedicine and e-Health, Astrobiology, Games for Health Journal.
- The fully-OA 'Reports' family - Gold OA companions to established titles, including Neurotrauma Reports, Palliative Medicine Reports, Women's Health Reports, Telemedicine Reports, and Integrative Medicine Reports.
Open access and APCs
Mary Ann Liebert offers three OA routes, now administered through Sage:
- Gold OA (fully-OA journals) - roughly 20+ titles, led by the 'Reports' family, published under CC BY licenses.
- Hybrid OA - most legacy subscription titles offer an OA option per article; fees vary by journal, so check the journal's for-authors page.
- Green OA (self-archiving) - permitted; deposit terms follow the journal's policy, now aligned with Sage's author archiving rules.
Verified 2026 APC anchors for fully-OA titles (USD, before tax - always confirm on the journal's current price page):
| Journal | APC |
|---|---|
| Palliative Medicine Reports | ~$1,250 |
| Integrative Medicine Reports | ~$1,450 |
| Neurotrauma Reports | ~$1,750 |
| Telemedicine Reports | ~$2,500 |
| Women's Health Reports | ~$3,000 |
Waivers and discounts are available on request for authors who lack funding, and Liebert titles are progressively being added to Sage's read-and-publish (transformative) agreements - check the ESAC registry or ask your library whether your institution's Sage deal covers Liebert journals. Note that cOAlition S ended the Transformative Journal framework at the end of 2024, so OA-funding compliance now runs mainly through institutional agreements.
Peer review process
- Default model: single-anonymized peer review across most titles.
- Editorial structure: journals are editor-led with field-specialist boards; many titles are official journals of societies (e.g., Thyroid for the American Thyroid Association).
- Turnaround: varies by journal; specialty titles typically return a first decision in one to three months. Check the journal's page for current averages.
How to submit
- Pick the journal. Browse the Liebert portfolio on the Sage platform or use SciSpace journal pages to compare scope and metrics.
- Read the manuscript-preparation guide. Each title has its own instructions; most use Vancouver-style referencing.
- Prepare your manuscript. Liebert journal templates are available on SciSpace to match each title's format requirements.
- Submit online. Most Liebert titles have used ScholarOne Manuscripts; following the Sage acquisition, some journals are migrating to Sage's submission systems - the journal's author-instructions page tells you which portal to use.
- Track and revise. Status updates, reviewer reports, and revisions are handled in the same portal.
Ethics and integrity
Mary Ann Liebert is a member of COPE and OASPA, and its titles follow COPE guidelines on authorship, corrections, and retractions. As part of Sage, Liebert journals also fall under Sage's research-integrity policies, including image-integrity screening and data-availability statements on many titles. Predatory-risk assessments consistently rate Liebert as an established, legitimate specialty publisher.









